Arbutus Biopharma Corp - 8-K Filing
Arbutus terminates RSV patent agreement with Genevant for $1M fee after settling Moderna litigation (Items: 1.02 Termination of a Material Definitive Agreement, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ABUS